Trial Profile
An Extension Study to Evaluate Long Term Safety of Subcutaneous Tocilizumab in Patients With Giant Cell Arteritis Who Have Completed WA28119 Core Study in France, and Subsequently Having Flare or Persisting Disease Activity.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Giant cell arteritis
- Focus Adverse reactions
- Sponsors Roche
- 08 Oct 2019 Status changed from active, no longer recruiting to completed.
- 14 Feb 2019 Planned End Date changed from 20 Dec 2018 to 31 May 2019.
- 14 Feb 2019 Planned primary completion date changed from 20 Dec 2018 to 31 May 2019.